Ardelyx Announces Departure of Board Member

Rhea-AI Summary

Ardelyx, Inc. (Nasdaq: ARDX) announced the resignation of Dr. Geoffrey Block from the Board of Directors after nearly five years of service. Dr. Block is the Associate Chief Medical Director and Senior Vice President of Clinical Research and Medical Affairs at U.S. Renal Care. The company expressed gratitude for Dr. Block's contributions and highlighted his role in Ardelyx's evolution from a developmental, clinical-stage biopharmaceutical company to an established commercial entity. Dr. Block emphasized Ardelyx's favorable position following the U.S. FDA approval of XPHOZAH® (tenapanor), a phosphate absorption inhibitor for chronic kidney disease patients on dialysis.

WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Geoffrey Block, MD, is stepping down from the Board of Directors after nearly five years of service. Dr. Block currently serves as the Associate Chief Medical Director and Senior Vice President of Clinical Research and Medical Affairs at U.S. Renal Care.

“On behalf of our board and Ardelyx’s leadership team, we thank Geoff for his unwavering commitment and the instrumental role he played in helping guide and evolve Ardelyx from a developmental, clinical-stage biopharmaceutical company to an established commercial entity,” said David Mott, Chair of the Ardelyx Board of Directors. “It has been a pleasure working with Geoff, and I would personally like to thank him for his ongoing support.”

“I am very proud of this leadership team’s many accomplishments and am grateful for the opportunity to have served on the board of directors,” said Dr. Block. “Ardelyx is well-positioned for the future, following the U.S. FDA approval of the first-in-class phosphate absorption inhibitor XPHOZAH^® (tenapanor) which is a new option for the many patients with chronic kidney disease on dialysis, a community I have dedicated my career to serving. The time is right for me step down from the board of directors as Ardelyx embarks on its next phase.”

About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA^® (tenapanor) and XPHOZAH^® (tenapanor) as well as early-stage pipeline candidates. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin has received approval for PHOZEVEL^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com

FAQ

Who is stepping down from the Board of Directors at Ardelyx, Inc. (Nasdaq: ARDX)?

Dr. Geoffrey Block is stepping down from the Board of Directors after nearly five years of service.

What is the significance of Dr. Block's resignation for Ardelyx, Inc. (Nasdaq: ARDX)?

Dr. Block's resignation marks the departure of a key figure who played an instrumental role in Ardelyx's transition from a developmental company to an established commercial entity.

What is the recent achievement mentioned in the press release for Ardelyx, Inc. (Nasdaq: ARDX)?

The U.S. FDA approval of XPHOZAH® (tenapanor), a phosphate absorption inhibitor for chronic kidney disease patients on dialysis, is highlighted as a significant achievement.

What is Dr. Geoffrey Block's current position?

Dr. Block currently serves as the Associate Chief Medical Director and Senior Vice President of Clinical Research and Medical Affairs at U.S. Renal Care.

What is the reason for Dr. Block's decision to step down from the Board of Directors at Ardelyx, Inc. (Nasdaq: ARDX)?

Dr. Block mentioned that Ardelyx is well-positioned for the future following the FDA approval of XPHOZAH® (tenapanor) and that it is the right time for him to step down as the company embarks on its next phase.